Malignant fibrous histiocytoma epidemiology and demographics

	Malignant fibrous histiocytoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Malignant Fibrous Histiocytoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Malignant fibrous histiocytoma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Malignant fibrous histiocytoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Malignant fibrous histiocytoma epidemiology and demographics
CDC on Malignant fibrous histiocytoma epidemiology and demographics
Malignant fibrous histiocytoma epidemiology and demographics in the news
Blogs on Malignant fibrous histiocytoma epidemiology and demographics
Directions to Hospitals Treating Malignant fibrous histiocytoma
Risk calculators and risk factors for Malignant fibrous histiocytoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Overview

Myelodysplastic syndrome commonly affects individuals between 32-80 (mean 59 years) years of age.^[1]

Males are more commonly affected with myelodysplastic syndrome than females. The male to female ratio is 1.2:1.^[1]

↑ ^1.0 ^1.1 Malignant fibrous histiocytoma. Dr Henry Knipe and A.Prof Frank Gaillard et al. Radiopaedia (2015). http://radiopaedia.org/articles/malignant-fibrous-histiocytoma. Accessed on December 17, 2015